The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...

A clinical-stage biotech company based in Redwood City, California, developing tissue-restorative biologics for chronic ...

California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research ...

Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Juvena Therapeutics & Eli Lilly and Company ink research collaboration focused on muscle health: Redwood City, California Saturday, June 14, 2025, 15:00 Hrs [IST] Juvena Therapeut ...

Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena Collaboration aims to accelerate the ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Alector said it promoted Business Chief Neil Berkley as interim chief financial officer. Berkeley will succeed Marc Grasso, who gave notice of his decision to resign from the position to pursue ...

Obesity-drug makers have signed deals that could be worth $812 million to a South San Francisco company and more than $650 million to a Redwood City company. How a $200K UC Berkeley grant could launch ...